{"ticker": {"uuid": "90013774-3c26-4098-bd34-cda55918f508", "symbol": "ARGX", "name": "argenx NV ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Argenx stock trades near recent highs as Vyvgart growth supports outlook", "summary": "Argenx stock is trading near recent highs, driven by strong growth in Vyvgart sales and a robust cash position. The company reported a significant increase in Vyvgart net product revenue and total revenue in Q1 2024, alongside a narrowing net loss. Argenx continues to invest heav", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-near-recent-highs-as-vyvgart-growth-supports-outlook/69827146", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T19:11:58", "published_display": "21 Jul 2026 19:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Q1 2026 revenue grows and new Vyvgart data supports pipeline", "summary": "Argenx stock is trading steadily following a mix of rising Q1 2026 revenue and continued clinical progress with its drug Vyvgart. The company reported a significant increase in total revenue for Q1 2026, primarily driven by Vyvgart sales, while also maintaining high investment in", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-q1-2026-revenue-grows-and-new-vyvgart-data/69822878", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T15:42:00", "published_display": "21 Jul 2026 15:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Vyvgart growth underpins revenue outlook", "summary": "Argenx stock performance is characterized by the strong revenue growth of its drug Vyvgart, which underpins the company's financial outlook despite widening operating losses due to significant R&D investments. The company is transitioning from a development-stage biotech to a com", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-vyvgart-growth-underpins-revenue-outlook/69815962", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T21:04:00", "published_display": "20 Jul 2026 21:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades near recent highs as Vyvgart growth drives revenue", "summary": "Argenx stock is trading near recent highs, supported by strong revenue growth driven primarily by its autoimmune therapy Vyvgart. While the company is experiencing significant top-line expansion, operating expenses are also rising due to global launches and clinical development, ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-near-recent-highs-as-vyvgart-growth-drives-revenue/69812269", "source_name": "ad-hoc-news.de", "published_at": "2026-07-20T11:39:45", "published_display": "20 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as investors weigh recent revenue growth and clinical pipeline progress", "summary": "Argenx stock is holding steady as investors consider the company's strong revenue growth, driven by its lead autoimmune therapy, and its ongoing investments in a deep immunology pipeline. The company's financial health, including substantial cash reserves, supports its capital-in", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-investors-weigh-recent-revenue-growth-and/69807094", "source_name": "ad-hoc-news.de", "published_at": "2026-07-19T18:11:33", "published_display": "19 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as latest earnings detail growing immunology revenue", "summary": "Argenx stock is holding steady, driven by strong growth in immunology revenue, particularly from its FcRn antibody franchise. The company reported double-digit top-line growth in Q1 2025 and 70% revenue increase in fiscal 2024, despite continued net losses due to heavy R&D invest", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-latest-earnings-detail-growing-immunology/69804221", "source_name": "ad-hoc-news.de", "published_at": "2026-07-19T13:35:00", "published_display": "19 Jul 2026 13:35", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Vyvgart growth and cash position shape outlook", "summary": "Argenx stock performance is influenced by the rapid revenue growth of its drug Vyvgart, primarily in autoimmune neuromuscular indications, and its substantial cash reserves funding an extensive clinical pipeline. The company reported a more than threefold increase in total revenu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-vyvgart-growth-and-cash-position-shape/69801939", "source_name": "ad-hoc-news.de", "published_at": "2026-07-19T09:02:06", "published_display": "19 Jul 2026 09:02", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades near record levels as oncology deal follows strong Q1 growth", "summary": "Argenx stock is trading near record levels after reporting strong growth in Q1 2026, with total revenue up 33% to $532 million and net income doubling. The company's financial health is also bolstered by a 2024 oncology collaboration and its flagship Vyvgart antibody therapy, whi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-near-record-levels-as-oncology-deal-follows-strong-q1/69787671", "source_name": "Ad Hoc News", "published_at": "2026-07-17T13:51:12", "published_display": "17 Jul 2026 13:51", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Argenx stock trades steady as Vyvgart growth supports long term revenue outlook", "summary": "Argenx stock is holding steady, driven by the strong revenue growth of its Vyvgart therapy for autoimmune diseases, which has seen double-digit and even triple-digit increases. Despite rapid top-line growth, the company continues to report operating losses due to significant inve", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-vyvgart-growth-supports-long-term-revenue/69782121", "source_name": "Ad Hoc News", "published_at": "2026-07-16T18:10:21", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026", "summary": "argenx announced that it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half-year 2026 financial results and provide a second-quarter business update. The webcast will be accessible on the Investors section", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328217/0/en/argenx-to-report-half-year-2026-financial-results-and-second-quarter-business-update-on-july-23-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T14:12:12", "published_display": "16 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx Sets July 23 Webcast for Second-Quarter Business Update", "summary": "argenx (Euronext & Nasdaq: ARGX) announced it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET). The company will discuss its half-year 2026 financial results and provide a second-quarter business update. Investors can acces", "url": "https://www.stocktitan.net/news/ARGX/argenx-to-report-half-year-2026-financial-results-and-second-quarter-7ixk8chs28sr.html", "source_name": "Stock Titan", "published_at": "2026-07-16T04:42:39", "published_display": "16 Jul 2026 04:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs", "summary": "", "url": "https://finance.yahoo.com/technology/ai/articles/chai-discovery-enters-collaboration-agreement-120900385.html", "source_name": "Business Wire", "published_at": "2026-07-15T12:09:00+00:00", "published_display": "15 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)", "summary": "Two healthcare companies, Argenx Se (ARGX) and Nuvation Bio (NUVB), have received bullish sentiments from analysts. Argenx Se was reiterated with a Buy rating and a price target of $1146.00 by TD Cowen, while Nuvation Bio also received a maintained Buy rating and a price target o", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NUVB/pressreleases/3265139/analysts-top-healthcare-picks-argenx-se-argx-nuvation-bio-nuvb/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T02:10:21", "published_display": "15 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Omnicell (OMCL)", "summary": "Analyst sentiment in the Healthcare sector is optimistic for Argenx Se (ARGX), Omnicell (OMCL), and Supernus Pharmaceuticals (SUPN). Bank of America Securities analysts have issued Buy ratings for all three companies, setting price targets that suggest significant upside from cur", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARGX/pressreleases/3268949/analysts-are-bullish-on-top-healthcare-stocks-argenx-se-argx-omnicell-omcl/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T01:45:53", "published_display": "15 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx (ENXTBR:ARGX) Following VYVGART Platform Hopes And A Pricey Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNVWlMOXFMRnpYa3l4SzBHUXV5cnI3dEZrRk1mRXlmeVdkS2R2Mm5Zd19FRXozazhsbFpXYmRhNEFQSDBURWxkTU82Z0hiQ2JwNGNIUmxoMERnWUxQNFVmNkhLNDFkMUlhMjVHRXFYZWx1anRYaVBoaVF1a2lyZmN4RW9sVUtJQ0R4YXhObVQwS0dGTmhHRWZUYnJib25jWDJ5T2JB?oc=5", "source_name": "Market source", "published_at": "2026-07-13T14:09:25+00:00", "published_display": "13 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE (ARGX) Stock Analysis: A Biotech Powerhouse With 19.64% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNQmdfbTVZN0VNQWxsMjdnMGpsOG11dG1DQV9vaVBhR19SVXNsbmU3aG1aQkozanBPTzMzdWJmd3BjamV3V0tIaXFWQjh1b1BhZ0U4Q191emlaOGxZZ0NQQTB4cTdlaElnUXlaWFpscWpVNG5jVUMxWS1kQm40UWt5V20tRlZuUVVjWl9GaVVIZF9jUXJ0R2gxeEVTTWVwY2ktTGRYUlhEMXRSVThzYWdmNWxTNjF5WlJLYVZyVGZORXlqN2VLYnFILQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:42+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Argenx (ARGX) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRzB3SlhmTkViSEFOUldxV1BnQ2JmOExRYmdoYUEzV1BOR3Z0OHdBN2dyQTJTN29GekVsZXd5cndhMXZqZW9POE1nd0FRRzBkRG1yTzFQTFdUX08yTEV2V2luOXFTbVFHSG80QWVmQUlNZ0g3MzkzdEFuWFlkcjM1Smt3SmxUTjI3NXptYXJXQW14QnY0bTZtZUFoVVBZZ2Fk?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Argenx: A Biotech Powerhouse Poised for Broad Expansion", "summary": "Argenx (ARGX) is positioned for significant growth, driven by its lead FcRn blocker, VYVGART, which is expanding into new indications like ocular myasthenia gravis (oMG) and seronegative generalized myasthenia gravis (gMG). The company's robust pipeline, featuring empasiprubart a", "url": "https://www.kavout.com/market-lens/argenx-a-biotech-powerhouse-poised-for-broad-expansion", "source_name": "Kavout | AI", "published_at": "2026-07-11T14:39:19", "published_display": "11 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock reflects biotech growth story amid global autoimmune focus", "summary": "Argenx, a biotech company specializing in antibody-based treatments for autoimmune diseases, is positioned in the high-risk, high-reward segment of global biotech with a dual listing on Euronext Brussels and Nasdaq. The company's focus on precision medicine and long-term care for", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-reflects-biotech-growth-story-amid-global-autoimmune-focus/69744602", "source_name": "ad-hoc-news.de", "published_at": "2026-07-11T12:39:19", "published_display": "11 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx Slides 3.5% as Investors Appear to Take Profits Ahead of Next Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQUThzTHNvWTRMVHZ0Ml85eHRoekV4dmNRb2lsaXJ5WllZelhGN1Q1VFRFYW81UzNrZi1ydF9tb2EyMmNoRk8tYWQtNTFsZFR5bVdPSkdUMnl3QnNkZ21lTnNrUFc1VVRxaFhmWjFEMkZIcnZ3eEUzSkE1eXE2Q3dIQllYTjR4NEM0T2syeEh3aWdXUE1MT3N4Zzl5VU03b1N0T3NYaFNVVUM3bzdDd3Zr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as autoimmune pipeline stays in focus", "summary": "Argenx stock continues to attract investor attention due to the biotechnology group's focus on antibody-based therapies for autoimmune diseases and its listing on Euronext Amsterdam. The company's strategy involves advancing a strong clinical portfolio and engaging in partnership", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-autoimmune-pipeline-stays-in-focus/69732271", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T13:17:20", "published_display": "09 Jul 2026 13:17", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE focuses on autoimmune therapies as global demand grows", "summary": "Argenx SE is expanding its portfolio of antibody-based treatments for autoimmune diseases, focusing on modulating the immune system and reducing harmful autoantibodies. The Nasdaq-listed biotech aims for global growth in immunology, balancing its core therapy with a diversified p", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-focuses-on-autoimmune-therapies-as-global-demand-grows/69726345", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T21:10:00", "published_display": "08 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx strengthens rare disease portfolio as investors track long-term growth", "summary": "Argenx SE is expanding its pipeline of antibody-based therapies for autoimmune and rare diseases, focusing on long-term revenue growth and market adoption. The company employs a multi-asset strategy to diversify risk and targets conditions with significant unmet medical needs. Ar", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-strengthens-rare-disease-portfolio-as-investors-track-long-term/69719799", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T05:40:21", "published_display": "08 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE focuses on autoimmune therapies as investors watch long-term growth", "summary": "Argenx SE is a biotechnology company specializing in antibody-based therapies for severe autoimmune diseases, attracting investor attention for its long-term growth prospects. The company uses a partnership-driven model and focuses on developing innovative treatments, with efgart", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-focuses-on-autoimmune-therapies-as-investors-watch-long-term/69714148", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:35:00", "published_display": "07 Jul 2026 14:35", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE outlines growth path as autoimmune portfolio expands", "summary": "Argenx SE is expanding its pipeline of antibody-based therapies for autoimmune diseases and growing its commercial presence. The company focuses on addressing high unmet medical needs with biologic drugs that modulate the immune system, using a staged development model and collab", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-outlines-growth-path-as-autoimmune-portfolio-expands/69711155", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T06:10:32", "published_display": "07 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE outlines autoimmune drug strategy as global demand for biologics grows", "summary": "Argenx SE is strategically expanding its focus on antibody-based therapies for severe autoimmune diseases and certain cancers, driven by increasing global demand for biologics due to an aging population and improved diagnostics. The company's business model centers on developing ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-outlines-autoimmune-drug-strategy-as-global-demand-for-biologics/69707880", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T18:09:57", "published_display": "06 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE deep dive on autoimmune drug pipeline and business model", "summary": "Argenx SE specializes in autoimmune disease treatments, leveraging its FcRn antibody technology and strategic partnerships to expand its pipeline and global reach. The company's business model combines in-house R&D with external collaborations for commercialization, focusing on d", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-deep-dive-on-autoimmune-drug-pipeline-and-business-model/69706048", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T15:40:54", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE (ARGX) Stock Analysis: A 11.59% Potential Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQbDJnQ1o2UUtLeFRWaUgxUU9pT0FkT3RoNS1aSFpyQUJrVWZnOFgwUHBnZjhPa1I2Ym03bWlKS3UyNTJiWWx4X3g5VXpFQldfWUdjTGlpX3o3RnFRa3FTYm9uY09NcWJGLWU3VC1XbzBkN1VnQk1Qd0ZaTU1nV2FvN092WmRVdkE3U0YzWFlsOV9uZWNGblA1b1RjRW5oZldIbUFNcHNQeHg4VnNQYk8zRF9waTJPX2JIaW9ZMXIySkRYM0VLRUxtYQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:07:23+00:00", "published_display": "06 Jul 2026 09:07", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE highlights immunology focus as global demand for rare disease therapies grows", "summary": "Argenx SE is advancing its antibody-based pipeline for autoimmune and rare diseases, focusing on specialist immunology. The company's strategy involves harnessing the immune system through engineered antibodies to modulate disease pathways and concentrate on rare and severe disor", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-highlights-immunology-focus-as-global-demand-for-rare-disease/69701887", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T05:41:05", "published_display": "06 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 90, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock holds the focus on its global immunology franchise.", "summary": "Argenx SE, a biotech company headquartered in the Netherlands, continues to center its focus on its global immunology franchise. The company's commercial base and pipeline, particularly its lead medicine Vyvgart, are key factors for investors. Argenx also has a broader developmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-holds-the-focus-on-its-global-immunology-franchise/69699721", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T18:40:14", "published_display": "05 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx (ARGX) 46th Annual William Blair Growth Stock Conference Summary", "summary": "argenx (ARGX) presented at the 46th Annual William Blair Growth Stock Conference, highlighting significant revenue and profit growth, with 17 consecutive quarters of revenue growth and a 63% recent quarterly increase. The company aims for 50,000 patients on treatment and 10 label", "url": "https://quartr.com/events/argenx-argx-46th-annual-william-blair-growth-stock-conference_F9Wnuo0u", "source_name": "Quartr", "published_at": "2026-07-04T12:10:39", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE outlines growth path in rare disease therapies", "summary": "Argenx SE, a biotechnology company, is focusing on building a global franchise in autoimmune and rare disease treatments using antibody-based therapies. The company aims to expand its presence in major markets, including the United States, through a blend of internal research and", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-outlines-growth-path-in-rare-disease-therapies/69679490", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T11:41:04", "published_display": "03 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock hits all-time high at 934.69 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNTTFSVFp2Q3F2UmQyeG43MmlLQjhSenJnX3NHVGZ4S1ZqZFBvSldhaDZGOFB1RFNoUmpIM0sxRUNRY3BZSVd4OUhFZXlBV2NncF9PQ3VDbXBKRnJheVd1UUVOdnZkdEUtSjJ4RmlJT2RJWkQxbkNkbGl3OWl6UWN1UlUyM2ZOT3pkVkllYm5JOG4tM1FtNkJDMWptTmFPOU1vbnc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNRW05WTFOM2tIOGV6UjdkbkRDTWdWQ2pyRlFNSXN1M1J1eDhMVHNLWU9feTJ2TnVPcFVvSmt4aWpHd0p2azF2My16aVdJWWZ3S0VTZHc2TU44THJrME5CZDkzVzJMV3h2ZmFHUnJsaUtSQW8tTHhlYmxNSFhEN2puUFVrX2piUlpGZFZ0OUwtTmhMODA4ZGNvNjBsRzlLaEkyMUZlSUdsai0xUnpJRWg1cTlESUpJT2t4LTJkaDIwWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock falls after myositis drug trial update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOVkJmZEpmTHkwZ3B0M3lOQ3NtT0l4cHhCTWpmbFh1LVh1VXZvQTV1aUw3Yk1TaUlCb2Vwd2xVQWpQamdMdjhiZm03WlVLVVU3M1JSVkVzUGF3RGJnZ2g0ZVZSdDkzcGkxSUFLZ0c1VHpOakEtTjdKUlZJbFFqbURzTU00MjkySWcxbUNVb1NYRU82Ynl1SGVVVFFWNEd6VFZJUEpuREd6WXpTQVR3aEREUEpkbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K argenx NV ADR For: 23 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNWWtuT2d6YXJNSVMtckxqUFB3WDFUdm5pczNvWXJ5X0Y0VWFsYTZzdFA3c2hiWlRyUjNlUDd1a1ZEVmdHT19XUWV2U09rQXFlRENkRGgyLXZkQXZoWU9mTjlJdWFEeC1hc3R2YkJ2TVVsNWJ4TXBlYUVsVTZ1c1dCMkxUX0VYMnl6cW1INFRIaFJJNVhia3gwZzBn?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPMmdqYk9lNjFwazk2UkF2TXJsYnlYVXBORFYwNktKX2pOUmRxZlZYTnptcTIydmtsdXkyV3NSV3BIWGZGYVllMDJWMEo1RUtSZlJ5cS1XZ05NVlZ3X2pfVDh2UlZDcHFtYnp6YWlHRDNHSG9lallRaUs5cmpTeHJEVnNBaXJRVkg5WTNIMnh3bw?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings call transcript: Argenx Q1 2026 beats EPS expectations, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQOVcxMk1ZeHE0emxURUV6aWp4NUxaNWpDUkJBeTBoeTEwcm05a3RHT3lZMXR1R0NDZm4ycEgwWTBFdVNYNFBkck12T1h0Q3ZqNmJMYkQxcUNuVGdNWTk3d0c0WndGVU1OQUo5X2VmLXdrQUVvTnF6MnQyeTBLYWJHbGdaM2MzTnFEaUNYcFh6UzNfTE1qTHA2YXpXOWlJOHdKTVdOV01XNFYwaEFibWh5b1VhR0JHcTdmYVp4bS02R0dCQkxpb0gwSQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RBC Capital maintains argenx stock price target at $890 on uptake potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOT1dEN21xLU5FTlN2T2ljWFhGYS1PV2lBMm9acmtCOFBZcDVacFk5MjE0Skd2azBaNzJaNkhCU0hMTEpJUXZmZ0Z1bENsazU0cmVBMXJNcjE1QWgyYVk3TE9wVkd5R3NFbTBWNFl0d1UtNnpnSU9VblBJcjRGU3ZRWlk2emVZeGs1ZXhBbzMxSjB1bWNWVHlHTnV3a1Bma211d0Vfd1h4VmJYc3JBSTY5ZmpYUXhyQ0ZWbGNGWUQ4dWtlRUp0cnFQaTk1d2pRR3c?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx (ARGX) tops earnings expectations despite slight revenue shortfall", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQY0JRQXI0Q2JCeUNxMktJcVB2LWp4cWJDbGJ4NEtwZXNVb2gwQXd4b0NhSzZfaU5hUWNTelE1WThiNlplc01pMGZ4NFhabFpBVnBoU3hrS3RJOFlIYms1NkExclkwTUdDa3ZfNVRzYXNoOFBWSF82R01yWkxfUS14dmpCVXFDM0hNZXBtNlUxYVhKTmE1TFZiRkk2QVRvM3oxUGZ6eWdHY29SbFE?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Argenx SE (ARGX) Slipped in Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNdkdYTHBKWjlVLWJJX3U4eFI3MWRnZ3hYZVhQN3lHc25uNlkzQzFOT3J2cnBsWEpWSGNrQ1dFemZSLTJwdlR1UzVKWFB0OGpXdFpjWTNqQkQwRnMtZDJabEwxczZuSmlXQ2hKdi04MzZMcmxHYVJHcG92NnBXRDBXcnREWXl2QVlOcmk4Z3prX3U0TUkzay10UVRhbw?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPemdsenZVZEdvYlFiZTM4cHNsdTR2aU5HSkVUR2xFZUFoZnZvQ0pLbXU3NEt0eEtSZmJvbnp4dlh0MV84WVFBT3ZWY0NuQWtQTThKcElielpxNjVGSW5wRmNKM0Ffb1hlMVFUQ1FGa1lKS3d4cU1zZjJJWGF5S1VmU2ZidWdpa0FaX1hj?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Argenx SE (ARGX) Stock Advanced on Commercial Execution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9LY0ZHYy1DdzNNLXBheVhJRWdHa1JQMjFiNXA5SHNXdExEeDdVa19hdVNQYkRsbVg1bVJvR2tFMkkxMURxaVVpUzZ1bUkyaGxUcGl6cUZMZ0hqVE1DUW5ndGtFNXhkZlNrYldXRG9QQzlYenpfNWxWY1RB?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Argenx stock trades near recent highs as Vyvgart growth supports outlook", "summary": "Argenx stock is trading near recent highs, driven by strong growth in Vyvgart sales and a robust cash position. The company reported a significant increase in Vyvgart net product revenue and total revenue in Q1 2024, alongside a narrowing net loss. Argenx continues to invest heav", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-near-recent-highs-as-vyvgart-growth-supports-outlook/69827146", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T19:11:58", "published_display": "21 Jul 2026 19:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Q1 2026 revenue grows and new Vyvgart data supports pipeline", "summary": "Argenx stock is trading steadily following a mix of rising Q1 2026 revenue and continued clinical progress with its drug Vyvgart. The company reported a significant increase in total revenue for Q1 2026, primarily driven by Vyvgart sales, while also maintaining high investment in", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-q1-2026-revenue-grows-and-new-vyvgart-data/69822878", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T15:42:00", "published_display": "21 Jul 2026 15:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Vyvgart growth underpins revenue outlook", "summary": "Argenx stock performance is characterized by the strong revenue growth of its drug Vyvgart, which underpins the company's financial outlook despite widening operating losses due to significant R&D investments. The company is transitioning from a development-stage biotech to a com", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-vyvgart-growth-underpins-revenue-outlook/69815962", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T21:04:00", "published_display": "20 Jul 2026 21:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades near recent highs as Vyvgart growth drives revenue", "summary": "Argenx stock is trading near recent highs, supported by strong revenue growth driven primarily by its autoimmune therapy Vyvgart. While the company is experiencing significant top-line expansion, operating expenses are also rising due to global launches and clinical development, ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-near-recent-highs-as-vyvgart-growth-drives-revenue/69812269", "source_name": "ad-hoc-news.de", "published_at": "2026-07-20T11:39:45", "published_display": "20 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as investors weigh recent revenue growth and clinical pipeline progress", "summary": "Argenx stock is holding steady as investors consider the company's strong revenue growth, driven by its lead autoimmune therapy, and its ongoing investments in a deep immunology pipeline. The company's financial health, including substantial cash reserves, supports its capital-in", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-investors-weigh-recent-revenue-growth-and/69807094", "source_name": "ad-hoc-news.de", "published_at": "2026-07-19T18:11:33", "published_display": "19 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as latest earnings detail growing immunology revenue", "summary": "Argenx stock is holding steady, driven by strong growth in immunology revenue, particularly from its FcRn antibody franchise. The company reported double-digit top-line growth in Q1 2025 and 70% revenue increase in fiscal 2024, despite continued net losses due to heavy R&D invest", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-latest-earnings-detail-growing-immunology/69804221", "source_name": "ad-hoc-news.de", "published_at": "2026-07-19T13:35:00", "published_display": "19 Jul 2026 13:35", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Vyvgart growth and cash position shape outlook", "summary": "Argenx stock performance is influenced by the rapid revenue growth of its drug Vyvgart, primarily in autoimmune neuromuscular indications, and its substantial cash reserves funding an extensive clinical pipeline. The company reported a more than threefold increase in total revenu", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-vyvgart-growth-and-cash-position-shape/69801939", "source_name": "ad-hoc-news.de", "published_at": "2026-07-19T09:02:06", "published_display": "19 Jul 2026 09:02", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades near record levels as oncology deal follows strong Q1 growth", "summary": "Argenx stock is trading near record levels after reporting strong growth in Q1 2026, with total revenue up 33% to $532 million and net income doubling. The company's financial health is also bolstered by a 2024 oncology collaboration and its flagship Vyvgart antibody therapy, whi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-near-record-levels-as-oncology-deal-follows-strong-q1/69787671", "source_name": "Ad Hoc News", "published_at": "2026-07-17T13:51:12", "published_display": "17 Jul 2026 13:51", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as Vyvgart growth supports long term revenue outlook", "summary": "Argenx stock is holding steady, driven by the strong revenue growth of its Vyvgart therapy for autoimmune diseases, which has seen double-digit and even triple-digit increases. Despite rapid top-line growth, the company continues to report operating losses due to significant inve", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-vyvgart-growth-supports-long-term-revenue/69782121", "source_name": "Ad Hoc News", "published_at": "2026-07-16T18:10:21", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026", "summary": "argenx announced that it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half-year 2026 financial results and provide a second-quarter business update. The webcast will be accessible on the Investors section", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328217/0/en/argenx-to-report-half-year-2026-financial-results-and-second-quarter-business-update-on-july-23-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T14:12:12", "published_display": "16 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx Sets July 23 Webcast for Second-Quarter Business Update", "summary": "argenx (Euronext & Nasdaq: ARGX) announced it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET). The company will discuss its half-year 2026 financial results and provide a second-quarter business update. Investors can acces", "url": "https://www.stocktitan.net/news/ARGX/argenx-to-report-half-year-2026-financial-results-and-second-quarter-7ixk8chs28sr.html", "source_name": "Stock Titan", "published_at": "2026-07-16T04:42:39", "published_display": "16 Jul 2026 04:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs", "summary": "", "url": "https://finance.yahoo.com/technology/ai/articles/chai-discovery-enters-collaboration-agreement-120900385.html", "source_name": "Business Wire", "published_at": "2026-07-15T12:09:00+00:00", "published_display": "15 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)", "summary": "Two healthcare companies, Argenx Se (ARGX) and Nuvation Bio (NUVB), have received bullish sentiments from analysts. Argenx Se was reiterated with a Buy rating and a price target of $1146.00 by TD Cowen, while Nuvation Bio also received a maintained Buy rating and a price target o", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NUVB/pressreleases/3265139/analysts-top-healthcare-picks-argenx-se-argx-nuvation-bio-nuvb/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T02:10:21", "published_display": "15 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Omnicell (OMCL)", "summary": "Analyst sentiment in the Healthcare sector is optimistic for Argenx Se (ARGX), Omnicell (OMCL), and Supernus Pharmaceuticals (SUPN). Bank of America Securities analysts have issued Buy ratings for all three companies, setting price targets that suggest significant upside from cur", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARGX/pressreleases/3268949/analysts-are-bullish-on-top-healthcare-stocks-argenx-se-argx-omnicell-omcl/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T01:45:53", "published_display": "15 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx (ENXTBR:ARGX) Following VYVGART Platform Hopes And A Pricey Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNVWlMOXFMRnpYa3l4SzBHUXV5cnI3dEZrRk1mRXlmeVdkS2R2Mm5Zd19FRXozazhsbFpXYmRhNEFQSDBURWxkTU82Z0hiQ2JwNGNIUmxoMERnWUxQNFVmNkhLNDFkMUlhMjVHRXFYZWx1anRYaVBoaVF1a2lyZmN4RW9sVUtJQ0R4YXhObVQwS0dGTmhHRWZUYnJib25jWDJ5T2JB?oc=5", "source_name": "Market source", "published_at": "2026-07-13T14:09:25+00:00", "published_display": "13 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE (ARGX) Stock Analysis: A Biotech Powerhouse With 19.64% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNQmdfbTVZN0VNQWxsMjdnMGpsOG11dG1DQV9vaVBhR19SVXNsbmU3aG1aQkozanBPTzMzdWJmd3BjamV3V0tIaXFWQjh1b1BhZ0U4Q191emlaOGxZZ0NQQTB4cTdlaElnUXlaWFpscWpVNG5jVUMxWS1kQm40UWt5V20tRlZuUVVjWl9GaVVIZF9jUXJ0R2gxeEVTTWVwY2ktTGRYUlhEMXRSVThzYWdmNWxTNjF5WlJLYVZyVGZORXlqN2VLYnFILQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:42+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Argenx (ARGX) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRzB3SlhmTkViSEFOUldxV1BnQ2JmOExRYmdoYUEzV1BOR3Z0OHdBN2dyQTJTN29GekVsZXd5cndhMXZqZW9POE1nd0FRRzBkRG1yTzFQTFdUX08yTEV2V2luOXFTbVFHSG80QWVmQUlNZ0g3MzkzdEFuWFlkcjM1Smt3SmxUTjI3NXptYXJXQW14QnY0bTZtZUFoVVBZZ2Fk?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx: A Biotech Powerhouse Poised for Broad Expansion", "summary": "Argenx (ARGX) is positioned for significant growth, driven by its lead FcRn blocker, VYVGART, which is expanding into new indications like ocular myasthenia gravis (oMG) and seronegative generalized myasthenia gravis (gMG). The company's robust pipeline, featuring empasiprubart a", "url": "https://www.kavout.com/market-lens/argenx-a-biotech-powerhouse-poised-for-broad-expansion", "source_name": "Kavout | AI", "published_at": "2026-07-11T14:39:19", "published_display": "11 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock reflects biotech growth story amid global autoimmune focus", "summary": "Argenx, a biotech company specializing in antibody-based treatments for autoimmune diseases, is positioned in the high-risk, high-reward segment of global biotech with a dual listing on Euronext Brussels and Nasdaq. The company's focus on precision medicine and long-term care for", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-reflects-biotech-growth-story-amid-global-autoimmune-focus/69744602", "source_name": "ad-hoc-news.de", "published_at": "2026-07-11T12:39:19", "published_display": "11 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx Slides 3.5% as Investors Appear to Take Profits Ahead of Next Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQUThzTHNvWTRMVHZ0Ml85eHRoekV4dmNRb2lsaXJ5WllZelhGN1Q1VFRFYW81UzNrZi1ydF9tb2EyMmNoRk8tYWQtNTFsZFR5bVdPSkdUMnl3QnNkZ21lTnNrUFc1VVRxaFhmWjFEMkZIcnZ3eEUzSkE1eXE2Q3dIQllYTjR4NEM0T2syeEh3aWdXUE1MT3N4Zzl5VU03b1N0T3NYaFNVVUM3bzdDd3Zr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock trades steady as autoimmune pipeline stays in focus", "summary": "Argenx stock continues to attract investor attention due to the biotechnology group's focus on antibody-based therapies for autoimmune diseases and its listing on Euronext Amsterdam. The company's strategy involves advancing a strong clinical portfolio and engaging in partnership", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-trades-steady-as-autoimmune-pipeline-stays-in-focus/69732271", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T13:17:20", "published_display": "09 Jul 2026 13:17", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE focuses on autoimmune therapies as global demand grows", "summary": "Argenx SE is expanding its portfolio of antibody-based treatments for autoimmune diseases, focusing on modulating the immune system and reducing harmful autoantibodies. The Nasdaq-listed biotech aims for global growth in immunology, balancing its core therapy with a diversified p", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-focuses-on-autoimmune-therapies-as-global-demand-grows/69726345", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T21:10:00", "published_display": "08 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx strengthens rare disease portfolio as investors track long-term growth", "summary": "Argenx SE is expanding its pipeline of antibody-based therapies for autoimmune and rare diseases, focusing on long-term revenue growth and market adoption. The company employs a multi-asset strategy to diversify risk and targets conditions with significant unmet medical needs. Ar", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-strengthens-rare-disease-portfolio-as-investors-track-long-term/69719799", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T05:40:21", "published_display": "08 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE focuses on autoimmune therapies as investors watch long-term growth", "summary": "Argenx SE is a biotechnology company specializing in antibody-based therapies for severe autoimmune diseases, attracting investor attention for its long-term growth prospects. The company uses a partnership-driven model and focuses on developing innovative treatments, with efgart", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-focuses-on-autoimmune-therapies-as-investors-watch-long-term/69714148", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:35:00", "published_display": "07 Jul 2026 14:35", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE outlines growth path as autoimmune portfolio expands", "summary": "Argenx SE is expanding its pipeline of antibody-based therapies for autoimmune diseases and growing its commercial presence. The company focuses on addressing high unmet medical needs with biologic drugs that modulate the immune system, using a staged development model and collab", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-outlines-growth-path-as-autoimmune-portfolio-expands/69711155", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T06:10:32", "published_display": "07 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE outlines autoimmune drug strategy as global demand for biologics grows", "summary": "Argenx SE is strategically expanding its focus on antibody-based therapies for severe autoimmune diseases and certain cancers, driven by increasing global demand for biologics due to an aging population and improved diagnostics. The company's business model centers on developing ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-outlines-autoimmune-drug-strategy-as-global-demand-for-biologics/69707880", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T18:09:57", "published_display": "06 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE deep dive on autoimmune drug pipeline and business model", "summary": "Argenx SE specializes in autoimmune disease treatments, leveraging its FcRn antibody technology and strategic partnerships to expand its pipeline and global reach. The company's business model combines in-house R&D with external collaborations for commercialization, focusing on d", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-deep-dive-on-autoimmune-drug-pipeline-and-business-model/69706048", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T15:40:54", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE (ARGX) Stock Analysis: A 11.59% Potential Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQbDJnQ1o2UUtLeFRWaUgxUU9pT0FkT3RoNS1aSFpyQUJrVWZnOFgwUHBnZjhPa1I2Ym03bWlKS3UyNTJiWWx4X3g5VXpFQldfWUdjTGlpX3o3RnFRa3FTYm9uY09NcWJGLWU3VC1XbzBkN1VnQk1Qd0ZaTU1nV2FvN092WmRVdkE3U0YzWFlsOV9uZWNGblA1b1RjRW5oZldIbUFNcHNQeHg4VnNQYk8zRF9waTJPX2JIaW9ZMXIySkRYM0VLRUxtYQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:07:23+00:00", "published_display": "06 Jul 2026 09:07", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE highlights immunology focus as global demand for rare disease therapies grows", "summary": "Argenx SE is advancing its antibody-based pipeline for autoimmune and rare diseases, focusing on specialist immunology. The company's strategy involves harnessing the immune system through engineered antibodies to modulate disease pathways and concentrate on rare and severe disor", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-highlights-immunology-focus-as-global-demand-for-rare-disease/69701887", "source_name": "AD HOC NEWS", "published_at": "2026-07-06T05:41:05", "published_display": "06 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 90, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock holds the focus on its global immunology franchise.", "summary": "Argenx SE, a biotech company headquartered in the Netherlands, continues to center its focus on its global immunology franchise. The company's commercial base and pipeline, particularly its lead medicine Vyvgart, are key factors for investors. Argenx also has a broader developmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-stock-holds-the-focus-on-its-global-immunology-franchise/69699721", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T18:40:14", "published_display": "05 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "argenx (ARGX) 46th Annual William Blair Growth Stock Conference Summary", "summary": "argenx (ARGX) presented at the 46th Annual William Blair Growth Stock Conference, highlighting significant revenue and profit growth, with 17 consecutive quarters of revenue growth and a 63% recent quarterly increase. The company aims for 50,000 patients on treatment and 10 label", "url": "https://quartr.com/events/argenx-argx-46th-annual-william-blair-growth-stock-conference_F9Wnuo0u", "source_name": "Quartr", "published_at": "2026-07-04T12:10:39", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx SE outlines growth path in rare disease therapies", "summary": "Argenx SE, a biotechnology company, is focusing on building a global franchise in autoimmune and rare disease treatments using antibody-based therapies. The company aims to expand its presence in major markets, including the United States, through a blend of internal research and", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-outlines-growth-path-in-rare-disease-therapies/69679490", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T11:41:04", "published_display": "03 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock hits all-time high at 934.69 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNTTFSVFp2Q3F2UmQyeG43MmlLQjhSenJnX3NHVGZ4S1ZqZFBvSldhaDZGOFB1RFNoUmpIM0sxRUNRY3BZSVd4OUhFZXlBV2NncF9PQ3VDbXBKRnJheVd1UUVOdnZkdEUtSjJ4RmlJT2RJWkQxbkNkbGl3OWl6UWN1UlUyM2ZOT3pkVkllYm5JOG4tM1FtNkJDMWptTmFPOU1vbnc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNRW05WTFOM2tIOGV6UjdkbkRDTWdWQ2pyRlFNSXN1M1J1eDhMVHNLWU9feTJ2TnVPcFVvSmt4aWpHd0p2azF2My16aVdJWWZ3S0VTZHc2TU44THJrME5CZDkzVzJMV3h2ZmFHUnJsaUtSQW8tTHhlYmxNSFhEN2puUFVrX2piUlpGZFZ0OUwtTmhMODA4ZGNvNjBsRzlLaEkyMUZlSUdsai0xUnpJRWg1cTlESUpJT2t4LTJkaDIwWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx stock falls after myositis drug trial update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOVkJmZEpmTHkwZ3B0M3lOQ3NtT0l4cHhCTWpmbFh1LVh1VXZvQTV1aUw3Yk1TaUlCb2Vwd2xVQWpQamdMdjhiZm03WlVLVVU3M1JSVkVzUGF3RGJnZ2g0ZVZSdDkzcGkxSUFLZ0c1VHpOakEtTjdKUlZJbFFqbURzTU00MjkySWcxbUNVb1NYRU82Ynl1SGVVVFFWNEd6VFZJUEpuREd6WXpTQVR3aEREUEpkbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K argenx NV ADR For: 23 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNWWtuT2d6YXJNSVMtckxqUFB3WDFUdm5pczNvWXJ5X0Y0VWFsYTZzdFA3c2hiWlRyUjNlUDd1a1ZEVmdHT19XUWV2U09rQXFlRENkRGgyLXZkQXZoWU9mTjlJdWFEeC1hc3R2YkJ2TVVsNWJ4TXBlYUVsVTZ1c1dCMkxUX0VYMnl6cW1INFRIaFJJNVhia3gwZzBn?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPMmdqYk9lNjFwazk2UkF2TXJsYnlYVXBORFYwNktKX2pOUmRxZlZYTnptcTIydmtsdXkyV3NSV3BIWGZGYVllMDJWMEo1RUtSZlJ5cS1XZ05NVlZ3X2pfVDh2UlZDcHFtYnp6YWlHRDNHSG9lallRaUs5cmpTeHJEVnNBaXJRVkg5WTNIMnh3bw?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Argenx Q1 2026 beats EPS expectations, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQOVcxMk1ZeHE0emxURUV6aWp4NUxaNWpDUkJBeTBoeTEwcm05a3RHT3lZMXR1R0NDZm4ycEgwWTBFdVNYNFBkck12T1h0Q3ZqNmJMYkQxcUNuVGdNWTk3d0c0WndGVU1OQUo5X2VmLXdrQUVvTnF6MnQyeTBLYWJHbGdaM2MzTnFEaUNYcFh6UzNfTE1qTHA2YXpXOWlJOHdKTVdOV01XNFYwaEFibWh5b1VhR0JHcTdmYVp4bS02R0dCQkxpb0gwSQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital maintains argenx stock price target at $890 on uptake potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOT1dEN21xLU5FTlN2T2ljWFhGYS1PV2lBMm9acmtCOFBZcDVacFk5MjE0Skd2azBaNzJaNkhCU0hMTEpJUXZmZ0Z1bENsazU0cmVBMXJNcjE1QWgyYVk3TE9wVkd5R3NFbTBWNFl0d1UtNnpnSU9VblBJcjRGU3ZRWlk2emVZeGs1ZXhBbzMxSjB1bWNWVHlHTnV3a1Bma211d0Vfd1h4VmJYc3JBSTY5ZmpYUXhyQ0ZWbGNGWUQ4dWtlRUp0cnFQaTk1d2pRR3c?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argenx (ARGX) tops earnings expectations despite slight revenue shortfall", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQY0JRQXI0Q2JCeUNxMktJcVB2LWp4cWJDbGJ4NEtwZXNVb2gwQXd4b0NhSzZfaU5hUWNTelE1WThiNlplc01pMGZ4NFhabFpBVnBoU3hrS3RJOFlIYms1NkExclkwTUdDa3ZfNVRzYXNoOFBWSF82R01yWkxfUS14dmpCVXFDM0hNZXBtNlUxYVhKTmE1TFZiRkk2QVRvM3oxUGZ6eWdHY29SbFE?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Argenx SE (ARGX) Slipped in Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNdkdYTHBKWjlVLWJJX3U4eFI3MWRnZ3hYZVhQN3lHc25uNlkzQzFOT3J2cnBsWEpWSGNrQ1dFemZSLTJwdlR1UzVKWFB0OGpXdFpjWTNqQkQwRnMtZDJabEwxczZuSmlXQ2hKdi04MzZMcmxHYVJHcG92NnBXRDBXcnREWXl2QVlOcmk4Z3prX3U0TUkzay10UVRhbw?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPemdsenZVZEdvYlFiZTM4cHNsdTR2aU5HSkVUR2xFZUFoZnZvQ0pLbXU3NEt0eEtSZmJvbnp4dlh0MV84WVFBT3ZWY0NuQWtQTThKcElielpxNjVGSW5wRmNKM0Ffb1hlMVFUQ1FGa1lKS3d4cU1zZjJJWGF5S1VmU2ZidWdpa0FaX1hj?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Argenx SE (ARGX) Stock Advanced on Commercial Execution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9LY0ZHYy1DdzNNLXBheVhJRWdHa1JQMjFiNXA5SHNXdExEeDdVa19hdVNQYkRsbVg1bVJvR2tFMkkxMURxaVVpUzZ1bUkyaGxUcGl6cUZMZ0hqVE1DUW5ndGtFNXhkZlNrYldXRG9QQzlYenpfNWxWY1RB?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 52, "sentiment_summary": {"positive": 27, "negative": 2, "neutral": 23, "score": 62, "total": 52, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.96, "count": 24}, {"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 27, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 860.55, "latest_week": "2026-07-17", "one_week_move": -1.9, "four_week_move": -2.0, "twelve_week_move": 10.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.887694, "market_dynamics_buy_signal": false, "relative_strength": -3.092823, "fair_value_gap": 42.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.4784, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.9% over one week, -2.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 71, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "AD HOC NEWS", "count": 8}, {"label": "Ad-hoc-news.de", "count": 5}, {"label": "ad-hoc-news.de", "count": 5}, {"label": "Investing.com", "count": 5}, {"label": "Ad Hoc News", "count": 2}, {"label": "The Globe and Mail", "count": 2}, {"label": "DirectorsTalk Interviews", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 21}, {"label": "Analyst action", "count": 3}, {"label": "Macro sensitivity", "count": 3}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "62/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.9% over one week, -2.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Argenx stock trades near recent highs as Vyvgart growth supports outlook"}], "updated_at": "2026-07-22T06:10:03.629766+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}